Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Roger Lo and colleagues characterized the melanoma genome, transcriptome and epigenome to understand the landscape of acquired resistance to MAPK pathway inhibitors.
A study published inCancer Cellreports that two FDA-approved drugs — an antidepressant and an anticoagulant — synergize to promote autophagy and slow glioma progression in mice.
Chi Dang and colleagues show that MYC is involved in the regulation of the circadian clock, and its deregulated expression in cancer cells leads to a loss of cellular circadian rhythm and impacts cell metabolism.
Three papers have reported new data on resistance to bromodomain and extraterminal (BET) inhibitors and how best to use these inhibitors in combination therapy.
This Review discusses recent advances that shed new light on the relationship between centrosomes and cancer, raising the possibility that centrosome aberrations contribute to this disease in different ways than initially envisaged.
Liver tumorigenesis is complex and depends on the cellular origin of a tumour as well as on environmental influences. This Review discusses the origins of various primary liver cancers, integrating our current understanding of cells of origin, liver tumour genomics and the disrupted hepatic microenvironment.
This Opinion article outlines a set of research priorities, based on discussions held at the 2015 Helene Harris Memorial Trust Ovarian Cancer Action meeting, that the authors believe will reduce incidence and improve outcomes for women with high-grade serous ovarian cancer.
Most cancer genomics studies have focused on identifying the most important somatic mutations ('major drivers') that promote tumour growth. However, many cancer-associated mutations might instead have relatively weak tumour-promoting effects. This Opinion article highlights the existence of these mutations (termed 'mini drivers') and the functional effects that they might have.
What is the best approach to avoid resistance to therapies that target intracellular signalling pathways? In this Opinion article, Gonda and Ramsay argue that increased effort should be made to target transcriptional regulators directly.
